From lab to clinic: Enhancing CKD diagnosis and management through implementation of cystatin C

Description

Cystatin C offers a more reliable estimate of kidney function compared to creatinine alone, as it is unaffected by patient muscle mass, diet, or inflammation. Despite recommendations for its expanded use in the 2024 KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), the utilization of cystatin C in clinical practice remains low.

In this webinar, participants will learn how to overcome barriers to implementing cystatin C testing into a care setting and best practices to effectively manage the change in the estimation of glomerular filtration rate (GFR).

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory, pathologists, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Describe current guidelines for the evaluation and management of CKD and why cystatin C is recommended for the estimation of GFR.
• Identify barriers to the implementation of cystatin C for in-house testing and explain how to overcome them.
• Describe best practices for the introduction of cystatin C to estimate GFR including how to partner with clinicians and give an example of how one institution is using cystatin C in practice.

Faculty

Amy Pyle-Eilola, PhD, DABCC, FADLM
Chemistry Director
Nationwide Children's Hospital
Associate Professor
Wexner Medical Center, The Ohio State University
Columbus, OH

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Amy Pyle-Eilola, PhD, DABCC, FADLM
  • Honorarium/Expenses: QuidelOrtho

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID #4404. This activity was planned in accordance with ACCENT® Standards and Policies.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].